Barter, PJ and Ballantyne, CM and Carmena, R and Cabezas, MC and Chapman, MJ and Couture, P and De Graaf, J and Durrington, PN and Faergeman, O and Frohlich, J and Furberg, CD and Gagne, C and Haffner, SM and Humphries, SE and Jungner, I and Krauss, RM and Kwiterovich, P and Marcovina, S and Packard, CJ and Pearson, TA and Reddy, KS and Rosenson, R and Sarrafzadegan, N and Sniderman, AD and Stalenhoef, AF and Stein, E and Talmud, PJ and Tonkin, AM and Walldius, G and Williams, KMS (2006) Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J INTERN MED , 259 (3) 247 - 258. 10.1111/j.1365-2796.2006.0161.x.
Full text not available from this repository.
There is abundant evidence that the risk of atherosclerotic vascular disease is directly related to plasma cholesterol levels. Accordingly, all of the national and transnational screening and therapeutic guidelines are based on total or LDL cholesterol. This presumes that cholesterol is the most important lipoprotein-related proatherogenic risk variable. On the contrary, risk appears to be more directly related to the number of circulating atherogenic particles that contact and enter the arterial wall than to the measured concentration of cholesterol in these lipoprotein fractions. Each of the atherogenic lipoprotein particles contains a single molecule of apolipoprotein (apo) B and therefore the concentration of apo B provides a direct measure of the number of circulating atherogenic lipoproteins. Evidence from fundamental, epidemiological and clinical trial studies indicates that apo B is superior to any of the cholesterol indices to recognize those at increased risk of vascular disease and to judge the adequacy of lipid-lowering therapy. On the basis of this evidence, we believe that apo B should be included in all guidelines as an indicator of cardiovascular risk. In addition, the present target adopted by the Canadian guideline groups of an apo B < 90 mg dL(-1) in high-risk patients should be reassessed in the light of the new clinical trial results and a new ultra-low target of < 80 mg dL(-1) be considered. The evidence also indicates that the apo B/apo A-I ratio is superior to any of the conventional cholesterol ratios in patients without symptomatic vascular disease or diabetes to evaluate the lipoprotein-related risk of vascular disease.
|Title:||Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel|
|Keywords:||apo B, coronary heart disease, guidelines, LDL cholesterol, lipid-lowering therapy, LOW-DENSITY-LIPOPROTEIN, CORONARY-ARTERY-DISEASE, ISCHEMIC-HEART-DISEASE, APOLIPOPROTEIN-A-I, INSULIN-RESISTANCE ATHEROSCLEROSIS, FAMILIAL COMBINED HYPERLIPIDEMIA, NON-HDL CHOLESTEROL, CHEMISTRY STANDARDIZATION PROJECT, NUCLEAR-MAGNETIC-RESONANCE, LIPID-LOWERING THERAPY|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science|
Archive Staff Only: edit this record